Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 330

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 330
---
”) for the Arena ELOC On February 23, 2024, the Company entered into a common stock purchase agreement (the “Arena Purchase Agreement”) with Arena, pursuant to which we may sell and issue, and Arena is obligated to purchase, up to $ 25,000,000of Common Stock. The price of the shares purchased by Arena under the ELOC is 90% of various VWAP and closing price-based formulae, and requires a waiver, should the selling price be below $ 25.00per share. As consideration for Arena commitment to purchase shares of Common Stock pursuant to the Arena Purchase Agreement, in May 2024, the Company issued 3,456shares of Common Stock to Arena valued at $ 500,000, which is reflected as deferred offering costs on the accompanying consolidated balance sheet as of March 31, 2025 and December 31, 2024. The Company has sold no shares of Common Stock to Arena under the Arena ELOC during the three months ended March 31, 2025 and 2024. F-21 Sale of Pre-funded Warrants and Common Stock On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 2,551,020shares of its common stock, par value $ 0.0001per share (the “Common Stock”) or common stock equivalents in lieu thereof (the Company sold 300,000shares of its common stock and 2,251,020pre-funded warrants) ; and (ii) common warrants to purchase up to 2,551,020shares of common stock (the “Warrants”), at a combined public offering price of $ 1.96per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company and each investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received net proceeds of approximately $ 4.2million, which is net of offering costs and fees of $ 839,004. During the three months ended March 31, 2025, 300,000shares of common stock were purchased upon the closing of the Offering and